secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2022-10-12T23:59:59+00:00
Accession:  0001140361-22-036896
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA allows Galectin Therapeutics to proceed with Phase 2 trial of belapectin + Keytruda in head and neck cancer
--------------------------------------------------------------------------------

- FDA issued 'Study May Proceed' letter for Phase 2 trial of belapectin + pembrolizumab as first-line therapy for recurrent/metastatic PD-L1 positive head and neck squamous cell carcinoma.
- This IND is the company's second; prior investigator-initiated study provided rationale for combination.
- Company expects to complete enrollment in pivotal NAVIGATE trial in NASH cirrhosis around end of 2022.
- Company plans to engage potential partners for oncology program; financing and trial start could occur next year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036122036896/0001140361-22-036896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036122036896/ny20005256x3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-036896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer